To identify factors underlying the PRC2/EED inhibitor responsiveness, RNA-Seq analysis was performed for the control and BR0063-treated SWI/SNF LOF tumor cell lines (i.e., the sensitive cell lines DMS 114 and MFE-296, and the resistant cell lines NCI-H23, NCI-H1703, HEC-1-A, and EFE-184). This evidence concerns the gene SMARCA1 and neoplasm.